Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Ohio State University
•
NCI-CCC Thoracic Tumor Board Question
For a patient with metastatic NSCLC who had progression x2 at a single site treated w RT, would you switch systemic treatment?
Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation.
Answer from: Medical Oncologist at Community Practice
Continue immunotherapy.
Sign in or Register to read more
12858
Related Questions
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
When will you choose Tarlatamab over an alternative systemic therapy (e.g. lurbinectedin, topotecan) for relapsed ES SCLC?
Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?
How do you approach Tarlatamab use in an elderly patient with relapsed ES SCLC?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
Do you perform routine interval lung cancer screening in non-smokers who are 1st degree relatives of patients with non-smoking related lung cancers with known EGFR mutations?